MedElevator Войти в исследования
← Поиск публикаций

DOI 10.5114/wo.2026.162227

Медицинская библиотека · Contemporary oncology (Poznan, Poland) · 2026

Omitting the 5-fluorouracil bolus in metastatic colorectal cancer: impact on survival and toxicity in a retrospective multicentre cohort.

Sohaib Ahmed, Hebesh Eman H, Elabd Naglaa Said, Korani Omnia, Amin Mohamed T, Abd-Elhafiz Huda I, Badawy Amira M, Hosny Samar

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

The clinical value of the 5-fluorouracil (5-FU) bolus in modern multidrug regimens for metastatic colorectal cancer (mCRC) is uncertain, with concerns about added haematologic toxicity. This study assessed the impact of omitting the 5-FU bolus on survival and toxicity in patients receiving mFOLFOX6-based chemotherapy.

MATERIAL AND

METHODS

In this retrospective multicentre cohort, 267 mCRC patients treated between June 2020 and June 2024 at Menoufia University Hospitals and the National Cancer Institute, Cairo University, received either bolus-free nbFOLFOX (n = 141) or standard mFOLFOX6 (n = 126), with or without bevacizumab or anti-epidermal growth factor receptor therapy. Progression-free survival (PFS) and overall survival were analysed using Kaplan-Meier and Cox models.

RESULTS

Bolus omission produced a statistically significant but clinically small PFS improvement (mean 10.029 vs. 9.319 months; hazard ratio [HR] 1.532, 95% CI: 1.194-1.967; p = 0.001). Overall survival was similar between groups (mean 21.7 vs. 20.7 months; median 20.667 vs. 20.633 months; HR 1.242, 95% CI: 0.966-1.597; p = 0.089). Multivariate analysis identified bolus inclusion as an independent predictor of inferior PFS (HR 1.433, p = 0.006). High-grade neutropenia was significantly reduced with nbFOLFOX (14.9% vs. 25.4%, p = 0.019).

CONCLUSIONS

Omitting the 5-FU bolus does not compromise survival and reduces haematologic toxicity, supporting individualised treatment decisions, particularly in settings of drug shortages or high toxicity risk.

Для цитирования: Sohaib Ahmed, Hebesh Eman H, Elabd Naglaa Said, Korani Omnia, Amin Mohamed T, Abd-Elhafiz Huda I, Badawy Amira M, Hosny Samar. Omitting the 5-fluorouracil bolus in metastatic colorectal cancer: impact on survival and toxicity in a retrospective multicentre cohort.. Contemporary oncology (Poznan, Poland). 2026. DOI: 10.5114/wo.2026.162227.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.